RxDoctor Payments Data

Sorin Brener, MD

Interventional Cardiology · Brooklyn, NYNPI 1104930338

Payments from drug & device makers

$180,064in general payments, 2019–2025

Across 251 payments — averaging $717.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$114K
  • Abbott$43K
  • Medtronic$11K
  • Contego Medical, Inc$10K
  • Boston Scientific$542
  • Abiomed$440
  • plus $984 from 9 others

What the payments were for

  • Consulting fees$40,81625%
  • Speaking & faculty fees$98,25059%
  • Travel & lodging$16,89410%
  • Food & beverage$10,2616%
  • Education$180%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$180,064 in reported general payments places this provider in the 80th percentile of 382 interventional cardiology providers in New York.

See all interventional cardiology providers in New York

Medicare billing

Part B allowed, 2024
$29,682
Medicare patients
82
Services billed
203

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EntrestoSacubitril/Valsartan45$54,854
EliquisApixaban17$25,177
Metoprolol Succinate45$1,038
Valsartan-HydrochlorothiazideValsartan/Hydrochlorothiazide11$480
Atorvastatin Calcium40$473
ClopidogrelClopidogrel Bisulfate44$466
Pantoprazole Sodium17$374
Furosemide20$244
Lisinopril35$219
Amlodipine Besylate21$111
Carvedilol13$98

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$54$54,85445 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 382 interventional cardiology providers in New York.

Other interventional cardiology in Brooklyn

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →